Clinical trials: Buprenorphine
Chronic Pain, Opioid Addiction
Yoga for Pain and Opioid Dependence
This study is designed to develop an effective adjunctive treatment using yoga for chronic pain and opioid dependence.
- Trial name
- Yoga (NCT01590251)
- Testing
- Yoga, Educational Counseling
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Yale University
Opiate Dependence
Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence
The purpose of this study is to evaluate a very low dose naltrexone-buprenorphine treatment to transfer opioid dependent individuals to extended release naltrexone injection (Vivitrol).
- Trial name
- BUP/NXT-VIVI (NCT01690546)
- Testing
- very low dose naltrexone, extended release naltrexone, buprenorphine/naloxone
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Paolo Mannelli
Cancer
Safety and Effectiveness of Transdermal Buprenorphine in Cancer Pain
Buprenorphine transdermal patch is newly available in Taiwan in June 2017, the trade name is Transtec, and the available dosages are 35 μg/h and 52.5 μg/h.
- Trial name
- SOOTHE (NCT04315831)
- Testing
- Transdermal Buprenorphine
- Where
- Taiwan
- Volunteers
- 83 people
- Sponsor
- Taiwan Mundipharma Pharmaceuticals Ltd.
Opioid-Related Disorders
Alternate-Day Buprenorphine Administration. Phase VIII - 9
The purpose of this study is to evaluate open buprenorphine dosing with dose choice.
- Trial name
- NCT00000227
- Testing
- Buprenorphine
- Where
- United States
- Sponsor
- University of Vermont
Low Back Pain
Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients
Chronic pain patients are treated with prescription opioids and many exhibit opioid addiction. Currently, there are no evidence-based guidelines to better manage patients with chronic pain and coexistent opioid addiction.
- Trial name
- NCT01559454
- Testing
- Methadone, Buprenorphine/naloxone
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- State University of New York at Buffalo
Osteoarthritis
Buprenorphine Transdermal Patches (BTDS) in Subjects With Osteoarthritis Pain. Includes a 52-week Extension Phase.
The original objective of this study was to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (BTDS) 20 micrograms (mcg)/hour (h) in comparison to the buprenorphine transdermal system 5 mcg/h…
- Trial name
- NCT00320801
- Testing
- Buprenorphine transdermal patch
- Where
- 66 sites in United States
- Volunteers
- 188 people
- Sponsor
- Purdue Pharma LP
Opioid-use Disorder
Treatment of Pregnant Women With OUD
The investigators are testing two models of support for pregnant women with an opioid use disorder (OUD)
- Trial name
- SMART (NCT04240392)
- Testing
- Collaborative Care (CC), Extension for Community Healthcare Outcomes (ECHO)
- Where
- 11 sites in United States
- Volunteers
- 230 people
- Sponsor
- Yale University
Mindfulness, Guanfacine
Combined Guanfacine and Mindfulness Meditation as an Adjunct to Buprenorphine Maintenance in Opioid Use Disorder
The US is currently going through an opioid crisis, and while Medication Assisted Treatments such as buprenorphine (BUP) have proved highly effective at stabilizing the neurobiology underlying acute withdrawal, they have been…
- Conditions
- Mindfulness, Guanfacine, Opioid Use Disorder
- Trial name
- NCT06642181
- Testing
- Guanfacine pharmacotherapy, Mindfulness Oriented Recovery Enhancement (MORE)
- Where
- United States
- Volunteers
- 224 people
- Sponsor
- Rutgers, The State University of New Jersey
Opioid-use Disorder
OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder
This is an open-label, randomized, parallel-group multicenter study designed to evaluate the efficacy of the digital therapeutic OXD01 (MODIA) combined with sublingual buprenorphine/naloxone standard of care (SL BUP/NAL SOC)…
- Trial name
- NCT04948307
- Testing
- OXD01 digital therapy, Standard of Care
- Where
- 21 sites in United States
- Volunteers
- 437 people
- Sponsor
- Orexo AB
Pain
Comparison of Two Dosage Strengths of Transdermal Fentanyl Versus Transdermal Buprenorphine and Placebo in Acute Pain Models in Healthy Volunteers.
The primary objective of this pilot trial is to identify pain model(s) which allow(s) to compare and differentiate the analgesic effects between transdermal fentanyl 25µg/h, transdermal fentanyl 12µg/h and placebo in a dose…
- Trial name
- NCT00886002
- Testing
- Fentanyl; Buprenorphine; Naloxone
- Volunteers
- 20 people
- Sponsor
- Janssen-Cilag A.G., Switzerland
Opioid-Related Disorders
Treating Chronic Pain in Buprenorphine Patients in Primary Care Settings
Treating Opioid Patients' Pain and Sadness (TOPPS) focuses on the relationship of pain, depression, opioid and other substance misuse, and functioning.
- Trial name
- TOPPS (NCT03698669)
- Testing
- Treating Opioid Patients' Pain and Sadness (TOPPS), Health Education (HE)
- Where
- 2 sites in United States
- Volunteers
- 163 people
- Sponsor
- Boston University
Opioid-use Disorder, Overdose
Rapid Initiation of Drug Treatment Engagement
The proposed research will evaluate the ability of a mobile, rapid induction procedure to engage individuals in ongoing medication assisted treatment.
- Trial name
- RIDE (NCT03908437)
- Testing
- buprenorphine/naloxone
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- University of Pennsylvania
Opioid Use Disorder, Opioid Use
Effects of Lemborexant on Insomnia and Its Relationship to Mood and Behavior on Opioid Use Disorder Subjects
The goal of this clinical trial is to learn about how certain medications used to treat insomnia (e.g., Lemborexant) impact sleep, mood, and behavior in men and women with Opioid Use Disorder who are taking prescribed…
- Conditions
- Opioid Use Disorder, Opioid Use, Insomnia, Orexin Antagonist
- Trial name
- NCT06981195
- Testing
- Lemborexant 10 MG
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Virginia Commonwealth University
Chronic Pain, Opioid Use Disorder
Cannabidiol in Opioid Use Disorder and Chronic Pain With Buprenorphine
This is a randomized, placebo-controlled, crossover human laboratory study investigating the dose-dependent safety and acute effects of Cannabidiol (CBD) on measures of pain and opioid craving in outpatients with opioid use…
- Trial name
- NCT07886606
- Testing
- 400 mg Cannabidiol, 800 mg Cannabidiol, 1200 mg Cannabidiol
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Yale University
Opioid Use Disorder
Symptom-Inhibited Naloxone Induction (SINI) for Buprenorphine Initiation: A Feasibility Trial
The goal of this clinical study is to evaluate a new treatment approach called symptom inhibited naloxone induction (SINI) for people with opioid use disorder.
- Trial name
- NCT07439549
- Testing
- Naloxone Hydrochloride 0.4 MG/ML, Buprenorphine hydrochloride and naloxone hydrochloride dihydrate sublingual tablet (2 mg/0.5 mg and 8 mg/2 mg), Buprenorphine extended-release injection (300 mg/1.5 mL)
- Where
- 2 sites in Canada
- Volunteers
- 12 people
- Sponsor
- Pouya Azar
Drug Interaction, Analgesics
Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder
The purpose of this research study is to test the safety, tolerability, drug interactions with buprenorphine-naloxone, and effectiveness lemborexant when used to treat Opioid Use Disorder.
- Conditions
- Drug Interaction, Analgesics, Opioid Use Disorder
- Trial name
- NCT04818086
- Testing
- Lemborexant, Buprenorphine-naloxone
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Virginia Commonwealth University
Opioid-use Disorder
Clinical Decision Support for Opioid Use Disorders in Medical Settings: Usability Testing in an EMR
The primary objective of this pilot study is to program an opioid use disorder (OUD) clinical decision support (CDS) tool for use in an electronic medical record (EMR) and obtain high primary care physician (PCP) usability and…
- Trial name
- COMPUTE (NCT03559179)
- Testing
- Opioid Wizard
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- HealthPartners Institute
Opioid Use Disorder, Opioid Use
Novel Induction to Buprenorphine/Naloxone
Microdosing induction is a novel method of starting buprenorphine/naloxone without patients experiencing the opioid withdrawal that is a part of traditional induction.
- Conditions
- Opioid Use Disorder, Opioid Use, Opioid Abuse, Opioid Misuse
- Trial name
- NCT05644587
- Testing
- buprenorphine/naloxone
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Bicycle Health
Opioid-use Disorder, Opioid Dependence
SMART Effectiveness Trial
The current study piloted two psychosocial interventions developed to increase buprenorphine-naloxone adherence in individuals with opioid use disorder (OUD).
- Conditions
- Opioid-use Disorder, Opioid Dependence, Treatment Adherence
- Trial name
- NCT04464421
- Testing
- Contingency Management (CM), Brief Motivational Intervention + Substance Free Activities Session + Mindfulness-Based Adherence Promotion (BSM)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Karen Derefinko, PhD
Chronic Pain
Safety and Effectiveness of Buprenorphine Transdermal System in Elderly Subjects With Chronic Pain: Pilot Study.
This pilot study was designed to evaluate the effectiveness and tolerability of the buprenorphine transdermal system versus placebo on health outcomes in elderly residents in supervised living environments.
- Trial name
- NCT00313833
- Testing
- Buprenorphine transdermal delivery system
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- Purdue Pharma LP